PDCD1 and esophageal cancer: The remarkable therapeutic efficacy of immunotherapy (including programmed cell death-ligand 1 [PD-L1] and programmed cell death protein-1 [PD-1] inhibitors) in advanced esophageal cancer has prompted numerous researchers to investigate its potential application as neoadjuvant therapy (10).